Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma Inc. announced that the China National Medical Products Administration has accepted its New Drug Application for denifanstat (ASC40), a first-in-class fatty acid synthase inhibitor for treating moderate-to-severe acne vulgaris. This acceptance marks a significant milestone for Ascletis as it moves closer to commercializing denifanstat, which has shown promising results in Phase III trials, demonstrating significant efficacy and a favorable safety profile.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies, primarily targeting viral, liver, and cancer diseases. The company operates in the pharmaceutical industry and is known for its research and development of novel drug candidates.
Average Trading Volume: 7,641,674
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.32B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.